According to the State Food and Drug Administration, the State Food and Drug Administration recently carried out emergency review and approval in accordance with the relevant provisions of the Drug Administration Law and in accordance with the special drug approval procedures, and conditionally approved the combined packaging of the first class of innovative drug, Shenotevir tablets/Ritonavir tablets (trade name: Shenuoxin), which was declared by Hainan Xiansheng Pharmaceutical Co., Ltd The Class 1 innovative drug Deuteromidevir Hydrobromide Tablets (trade name: Mindevix) declared by Shanghai Wangshi Biomedical Technology Co., Ltd. was listed. The above two drugs are oral small molecule COVID-19 infection treatment drugs, which are used to treat adult patients with mild to moderate novel coronavirus infection (COVID-19). Patients should use drugs strictly according to the instructions under the guidance of doctors. The State Food and Drug Administration requires the marketing license holder to continue to carry out relevant research work, complete the conditional requirements within a time limit, and submit the follow-up research results in a timely manner. (Xinhua News Agency)